Phase i Study of the investigational nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors

Clinical Cancer Research

Volumn 22, Issue 4, 2016, Pages 847-857

  Sarantopoulos, John ^a   Shapiro, Geoffrey I ^b   Cohen, Roger B ^c   Clark, Jeffrey W ^d   Kauh, John S ^e   Weiss, Glen J ^f   Cleary, James M ^b   Mahalingam, Devalingam ^a   Pickard, Michael D ^g   Faessel, Héléne M ^g   Berger, Allison J ^g   Burke, Kristine ^g   Mulligan, George ^g   Dezube, Bruce J ^g   Harvey, R Donald ^e  

^a CTRC Institute for Drug Development   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e EMORY UNIVERSITY   (United States)

^f Virginia G Piper Cancer Center   (United States)

^g MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; PEVONEDISTAT; ((1S,2S,4R)-4-(4-((1S)-2,3-DIHYDRO-1H-INDEN-1-YLAMINO)-7H-PYRROLO(2,3-D)PYRIMIDIN-7-YL)-2-HYDROXYCYCLOPENTYL)METHYL SULPHAMATE; ANTINEOPLASTIC AGENT; CYCLOPENTANE DERIVATIVE; PYRIMIDINE DERIVATIVE; UBA3 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BONE MARROW SUPPRESSION; BREAST CANCER; COHORT ANALYSIS; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INSOMNIA; LIVER TOXICITY; MALE; MELANOMA; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR BIOPSY; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CYCLOPENTANES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PYRIMIDINES; TREATMENT OUTCOME; TUMOR BURDEN; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84964318313     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1338     Document Type: Article

References (45)

1. Ciechanover A. Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005;12:1178-90.
2. Hershko A. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ 2005; 12:1191-7.
3. Herrmann J, Lerman LO, Lerman A. Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res 2007;100:1276-91.
4. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res 2008;14:1649-57.
5. NalepaG, Rolfe M, Harper JW.Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006;5:596-613.
6. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
7. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009;15:3912-6.
8. Chiba T, Tanaka K. Cullin-based ubiquitin ligase and its control by NEDD8-conjugating system. Curr Protein Pept Sci 2004;5:177-84.
9. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6:9-20.
10. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci U S A 2000;97: 4579-84.
11. Read MA, Brownell JE, Gladysheva TB, Hottelet M, Parent LA, Coggins MB, et al. Nedd8 modification of cul-1 activates SCFbTrCP-dependent ubiquitination of IkBa. Mol Cell Biol 2000;20:2326-33.
12. Nishitani H, Sugimoto N, Roukos V, Nakanishi Y, Saijo M, Obuse C, et al. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J 2006;25:1126-36.
13. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24:7130-9.
14. Micel LN, Tentler JJ, Smith PG, Eckhardt GS. Role of ubiquitin ligases and the proteasome in oncogenesis: Novel targets for anticancer therapies. J Clin Oncol 2013;31:1231-8.
15. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: The NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 2010;37:102-11.
16. Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwartsmicroenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res 2014;20: 1576-89.
17. Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, et al. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther 2013;12: 1958-67.
18. Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, et al. The Nedd8-activating enzyme inhibitorMLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res 2012;72:3360-71.
19. Mackintosh C, Garcia-Dominguez DJ, Ordonez JL, Ginel-Picardo A, Smith PG, Sacristan MP, et al. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene 2013;32:1441-51.
20. McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, et al. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther 2012;11:942-51.
21. Milhollen MA, Traore T, Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-kB-dependent lymphoma. Blood 2010;116:1515-23.
22. Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, et al. Disrupting protein NEDDylationwith MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 2013;19: 3577-90.
23. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia. Blood 2010;115:3796-800.
24. WeiD, LiH, Yu J, Sebolt JT, Zhao L, Lawrence TS, et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 2012;72:282-93.
25. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010;70:10310-20.
26. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011;71:3042-51.
27. Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 2013;73: 225-34.
28. Traore T, Milhollen MA, Garnsey JJ, Berger A, Manfredi M, Cosmopolous K, et al. Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma. J Clin Oncol 2011;29, (suppl; abstr 8594)
29. Tentler JJ, Micel LN, Selby HM, Tan AC, Brunkow KL, Pitts TM, et al. Molecular determinants of response to the investigational small molecule inhibitor of Nedd8-activating enzyme (NAE) MLN4924 in melanoma cell lines and patient-derived tumor explant models [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10 (11 Suppl):Abstract nr B178.
30. O'Quigley J, Pepe M, Fisher L. Continual reassessmentmethod: A practical design for phase 1 clinical trials in cancer. Biometrics 1990;46:33-48.
31. National Cancer Institute Cancer Therapy Evaluation Program. National Cancer Institute Common Terminology Criteria for Adverse Events. Version 3, 2006.
32. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
33. Garrett-Mayer E. The continual reassessment method for dose-finding studies: A tutorial. Clin Trials 2006;3:57-71.
34. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in phase I dose-finding studies. Clin Trials 2008; 5:465-77.
35. Dou QP, Zonder JA. Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets 2014;14:517-36.
36. Shah JJ, Jakubowiak A, O'Connor OA, Orlowski RZ, Patterson M, Harvey RD, et al. MLN4924, a novel investigational NEDD8-activating enzyme (NAE) inhibitor, in patients with multiple myeloma and non-Hodgkin's lymphoma (NHL): Phase 1 dose-escalation study. Haematologica 2010; 95:(abstr 0394).
37. Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, et al. Pevonedistat (MLN4924), a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study. Br J Haematol 2015;169:534-43.
38. Onica T, Nichols K, Larin M, Ng L, Maslen A, Dvorak Z, et al. Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Mol Pharmacol 2008;73:451-60.
39. DeAngelo DJ, Erba HP, Marris M, Swords RT, Anwer F, Altman JK, et al. MLN4924, a novel investigational inhibitor Of NEDD8-activating enzyme (NAE), in adult patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): Results from multiple dosing schedules in a phase 1 study [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA. Washington, DC: ASH; 2014. Abstract nr 1443.
40. Bhatia S, Hamid O, Pavlick AC, Mulligan G, Smith PG, Pickard MD, et al. MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study. J Clin Oncol 29: 2011 (suppl; abstr 8529)
41. Swords RT, SavonaMR,Marris MB, ErbaHP, Berdeja JG, Foran JM, et al. Pevonedistat (MLN4924), an investigational, first-in-class NAE inhibitor, in combination with azacitidine in elderly patients with acute myeloid leukemia (AML) considered unfit for conventional chemotherapy: Updated results from the phase 1 C15009 trial [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA. Washington, DC: ASH; 2014. Abstract nr 2313.
42. Harvey RD, Lebovic D, Lonial S, Jakubowiak AJ, Pickard MD, McDonald A, et al. MLN4924, an investigational NEDD8-activating enzyme inhibitor, in patients with relapsed and/or refractory lymphoma or multiple myeloma: Phase 1 dose-escalation study of twice-weekly dosing. Haematologica 2012;91:(suppl; abstr 1060).
43. Smith PG, Traore T, Grossman S, Narayanan U, Carew JS, Lublinsky AR, et al. Azacitidine/decitabine synergism with the NEDD8-activating enzyme inhibitor MLN4924 in pre-clinical AML models abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA. Washington, DC: ASH; 2011. Abstract nr 578.
44. Garcia K, Blank JL, Bouck DC, Liu XJ, Sappal DS, Hather G, et al. Nedd8-activating enzyme inhibitorMLN4924 provides synergywith mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways. Mol Cancer Ther 2014;13:1625-35.
45. Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG, et al. Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol Cancer Res 2012;10:369-77.